Farmaceutisk Laboratorium Ferring A/S v. Reid Rowell, Inc.

142 F.R.D. 179, 20 U.S.P.Q. 2d (BNA) 1476, 1991 U.S. Dist. LEXIS 20033, 1991 WL 334853
CourtDistrict Court, N.D. Georgia
DecidedSeptember 12, 1991
DocketCiv. A. No. 1:89-CV-1972-JOF
StatusPublished

This text of 142 F.R.D. 179 (Farmaceutisk Laboratorium Ferring A/S v. Reid Rowell, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Georgia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Farmaceutisk Laboratorium Ferring A/S v. Reid Rowell, Inc., 142 F.R.D. 179, 20 U.S.P.Q. 2d (BNA) 1476, 1991 U.S. Dist. LEXIS 20033, 1991 WL 334853 (N.D. Ga. 1991).

Opinion

[180]*180ORDER

FORRESTER, District Judge.

This matter is before the court on plaintiffs motion to dismiss its complaint (or in the alternative to withdraw its opposition to defendant’s motion for summary judgment) and motion to dismiss defendant’s counterclaim for lack of subject matter jurisdiction.

I. STATEMENT OF THE CASE

On September 1, 1989 plaintiff Farma-ceutisk Laboratorium Ferring A/S (hereinafter “plaintiff”), assignee of U.S. Patent No. 4,496,553 (hereinafter “the ’553 patent”), filed the above-styled patent infringement action. Plaintiff’s complaint charges defendant Reid Rowell, Inc. (hereinafter “defendant”) with direct infringement of the ’553 patent under 35 U.S.C. § 271(a) and with inducing others to infringe under 35 U.S.C. § 271(b). Plaintiff’s lawsuit seeks to end defendant’s allegedly unauthorized use of the treatment methods claimed in the ’553 patent.

Defendant moved this court for summary judgment, on July 6,1990, contending that defendant itself does not practice the subject treatment method and, therefore, cannot be a direct infringer of the patent in suit under 35 U.S.C. § 271(a). Defendant further contends that since no infringement of the ’553 patent has taken place, defendant cannot be liable for inducing infringement in violation of 35 U.S.C. § 271(b).

Plaintiff now moves this court for leave to dismiss pursuant to Fed.R.Civ.P. 41(a)(2), with the stipulation that defendant’s current activities 1 are not acts of infringement. Plaintiff alleges that after conducting substantial discovery on certain issues of fact, it has concluded that it is unable to present sufficient evidence to rebut defendant’s contentions that defendant has not engaged in activities which are subject to claims of infringement of the patent-in-suit.

In the event that the motion to dismiss its complaint is granted,2 plaintiff contends that defendant’s counterclaim for declaratory judgment of patent invalidity, unen-forceability and non-infringement must also be dismissed for lack of subject matter jurisdiction, thereby disposing of all the claims in this case and rendering moot any outstanding discovery-related motions. Although defendant agrees that plaintiff's complaint should be dismissed, it strongly opposes dismissal of its counterclaim for a declaratory judgment pursuant to Fed. R.Civ.P. 41(a)(2). Plaintiff’s motions are now ripe for review.

II. CONCLUSIONS OF LAW

Both plaintiff’s motion for voluntary dismissal of its complaint and mandatory dismissal of defendant’s counterclaim were filed pursuant to Fed.R.Civ.P. 41(a)(2) which provides:

(2) By Order of the Court. Except as provided in paragraph (1) of the subdivision of this rule, an action shall not be dismissed at the plaintiff’s instance save upon order of the court and upon such terms and conditions as the court deems proper. If a counterclaim has been pleaded by a defendant prior to the service upon the defendant of the plaintiff’s motion to dismiss, the action shall not be dismissed against the defendant’s objection unless the counterclaim can remain pending for independent adjudication by the court. Unless otherwise specified in the order, a dismissal under this paragraph is without prejudice.

Fed.R.Civ.P. 41(a)(2). Where there exists an independent jurisdictional basis for the counterclaim, Rule 41 does not bar dismissal of plaintiff’s complaint. See McGraw-Edison Co. v. Performed Line Products Co., 362 F.2d 339 (9th Cir.1966). Here, there exists an independent jurisdictional basis for defendant’s counterclaim—federal [181]*181patent jurisdiction. See 28 U.S.C. § 1338;3 see also Schwartzkopf Development Corp. v. Ti-Coating, Inc., 800 F.2d 240, 244 (D.C.Cir.1986) (“[ajdjudication of a patent counterclaim is the exclusive province of the federal courts”). Since defendant’s counterclaim has a jurisdictional basis independent of the main action, the provision of Rule 41(a)(2) relating to counterclaims does not bar this court from dismissing plaintiff’s complaint or require the dismissal of defendant’s counterclaim.

Having determined that defendant’s counterclaim for declaratory judgment does not bar a voluntary dismissal of the complaint, this court must next consider the merits of plaintiff’s motion for voluntary dismissal. Rule 41(a)(2) permits a district court to dismiss an action without prejudice “upon such terms and conditions as the court deems proper.” The purpose of the rule “is primarily to prevent voluntary dismissals which unfairly affect the other side, and to permit the imposition of curative conditions.” McCants v. Ford Motor Co., Inc., 781 F.2d 855, 856 (11th Cir.1986) (citing Alamance Industries, Inc. v. Filene’s, 291 F.2d 142 (1st Cir.), cert. denied, 368 U.S. 831, 82 S.Ct. 53, 7 L.Ed.2d 33 (1961)). Thus, under Rule 41(a)(2) the plaintiff’s interest in dismissal is of little concern. See LeCompte v. Mr. Chip, Inc., 528 F.2d 601, 604 (5th Cir.1976). Notwithstanding the fact that plaintiff’s interests are not considered, it is nevertheless the rule in this circuit that “dismissal should be granted unless the defendant will suffer clear legal prejudice, other than the mere prospect of a second lawsuit, as a result.” McCants, 781 F.2d at 856-57.

The decision as to the terms and conditions that should be imposed, if any, is within the discretion of the trial court. “[T]he district court must exercise its broad equitable discretion under Rule 41(a)(2) to weigh the relevant equities and do justice between the parties in each case, imposing such costs and attaching such conditions to the dismissal as are deemed appropriate.” Id., at 857.

In the case sub judice, there is no claim that dismissal without prejudice of the above-styled action would result in substantial legal harm to the defendant.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
142 F.R.D. 179, 20 U.S.P.Q. 2d (BNA) 1476, 1991 U.S. Dist. LEXIS 20033, 1991 WL 334853, Counsel Stack Legal Research, https://law.counselstack.com/opinion/farmaceutisk-laboratorium-ferring-as-v-reid-rowell-inc-gand-1991.